More On Tengion's Tissue Engineering
MSNBC looks at tissue engineering company Tengion, who have been in the press since receiving significant venture funding. "Tengion plans to use the proceeds from the private stock sale to further the development of its lead products, which are organs and tissues derived from a patient's cells that can be used to replace a patient's diseased or impaired organ or tissue. The company's most advanced product - not yet tested in humans - is an autologous pediatric bladder. In biology, autologous refers to cells, tissues or proteins that are taken from the individual being treated and reimplanted in order to augment, repair or replace specific organs or tissues. ... Tengion's goal is to use regenerative medicine to enable people with organ and tissue failure to lead healthier lives without donor transplants or the side effects of current therapies."